[HTML][HTML] Targeting HER2-positive breast cancer: advances and future directions
SM Swain, M Shastry, E Hamilton - Nature reviews Drug discovery, 2023 - nature.com
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
Global burden of heart failure: a comprehensive and updated review of epidemiology
G Savarese, PM Becher, LH Lund… - Cardiovascular …, 2022 - academic.oup.com
Heart Failure (HF) is a multi-faceted and life-threatening syndrome characterized by
significant morbidity and mortality, poor functional capacity and quality of life, and high costs …
significant morbidity and mortality, poor functional capacity and quality of life, and high costs …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
[HTML][HTML] Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature)
B Smolarz, AZ Nowak, H Romanowicz - Cancers, 2022 - mdpi.com
Simple Summary Breast cancer is the most-commonly diagnosed malignant tumor in women
in the world, as well as the first cause of death from malignant tumors. The incidence of …
in the world, as well as the first cause of death from malignant tumors. The incidence of …
[HTML][HTML] Signaling pathways and therapeutic interventions in gastric cancer
Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …
Despite tremendous progress in diagnosis and therapeutic strategies and significant …
[HTML][HTML] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G Curigliano, D Lenihan, M Fradley, S Ganatra… - Annals of …, 2020 - Elsevier
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …
world. Evidence increasingly shows that these conditions are interlinked through common …
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools …
AR Lyon, S Dent, S Stanway, H Earl… - European journal of …, 2020 - Wiley Online Library
This position statement from the Heart Failure Association of the European Society of
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …
[HTML][HTML] Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
R Bradley, J Braybrooke, R Gray, R Hills, Z Liu… - The Lancet …, 2021 - thelancet.com
Background Trastuzumab targets the extracellular domain of the HER2 protein. Adding
trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer …
trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer …
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F Cardoso, S Kyriakides, S Ohno… - Annals of …, 2019 - annalsofoncology.org
In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …
HER2-targeted therapies—a role beyond breast cancer
DY Oh, YJ Bang - Nature reviews Clinical oncology, 2020 - nature.com
HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …